Reported Candidozyma auris cases in Europe rose to 1,346 in 2023 across 18 countries, with several reporting regional or national spread. The fungus is highly transmissible, difficult to control, and often resistant to antifungal drugs, posing a significant challenge for hospitals. Europe’s limited surveillance and laboratory capacity leave the true scale of infections uncertain.